

JHEP Reports

CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
Mouse anti-human MIF mAb	[1]	R&D Systems Wiesbaden-Nordenstadt, Germany	MAB289	#12302
biotinylated goat anti-human MIF pAb	[1]	R&D Systems Wiesbaden-Nordenstadt, Germany	BAF289	#932606
Anti-CD74 antibody	[2]	Santa Cruz	SC-5438	C-16
Anti-CD74 detection antibody	[2]	Santa Cruz	SC-6262	LN-2

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
-	-	-	-	-	-

1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
-	-	-	-	-	-	-

1.4 Sequence based reagents

Name	Sequence	Supplier
-	-	-

1.5 Biological samples

Description	Source	Identifier
-	-	-

1.6 Deposited data

Name of repository	Identifier	Link
-	-	-

1.7 Software

Software name	Manufacturer	Version
GraphPad	GraphPad, San Diego, CA, USA	5.01
IBM SPSS Statistics	IBM Corp., Armonk, NY, USA	25

1.8 Other (e.g. drugs, proteins, vectors etc.)

-	-	-
---	---	---

1.9 Please provide the details of the corresponding methods author for the manuscript:

Theresa H. Wirtz, MD; Medical Department III, RWTH Aachen University Hospital, Pauwelsstr. 30, 52074 Aachen, Germany, thwirtz@ukaachen.de; Tel.: +49-241-80-80861; Fax: +49-241-80-82455

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

No RCT

[1] Strussmann T, Tillmann S, Wirtz T, Bucala R, von Hundelshausen P, Bernhagen J. Platelets are a previously unrecognised source of MIF. *Thrombosis and haemostasis* 2013;110:1004-1013.

[2] Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. *Hepatology* 2014;59:580-591.